Clinical characteristics of cardioembolic transient ischemic attack: comparison with noncardioembolic transient
Takeshi Hayashi1, Yoshihide Sehara1, Yuji Kato1
1Department of Neurology and Cerebrovascular Medicine, Saitama Medical University, International Medical Center, Hidaka, Japan.
Insights
Cardioembolic transient ischemic attacks (TIA) share clinical features with noncardioembolic TIA. The CHADS2 score effectively identifies patients with cardioembolic TIA, aiding prompt treatment.
Area of Science:
- Neurology
- Cardiology
- Cerebrovascular Disease
Background:
- Transient ischemic attacks (TIA) can stem from cardiogenic cerebral embolism (cardioembolic TIA), accounting for 6%-31% of cases.
- Prompt TIA treatment is crucial to prevent subsequent strokes, necessitating accurate etiological diagnosis.
Purpose of the Study:
- To identify distinguishing features of cardioembolic TIA.
- To compare cardioembolic TIA with noncardioembolic TIA.
Main Methods:
- Retrospective review of tissue-defined TIA patients (April 2007-August 2013).
- Etiology categorized using Trial of Org 10172 in Acute Stroke Treatment criteria.
- Comparison of demographic, comorbidity, ABCD2, and CHADS2 scores between cardioembolic and noncardioembolic TIA groups.
Main Results:
- No significant differences in neurological symptoms or common comorbidities (hypertension, diabetes, dyslipidemia) between groups.
- Coronary and peripheral artery diseases were more prevalent in the cardioembolic TIA group.
- Higher CHADS2 scores were observed in the cardioembolic TIA group (P = .005).
Conclusions:
- Clinical presentation of cardioembolic and noncardioembolic TIA is largely similar.
- The CHADS2 score is a valuable tool for assessing the likelihood of cardioembolic TIA.
Background:
Previous studies show that 6%-31% of transient ischemic attacks (TIA) were caused by cardiogenic cerebral embolism (cardioembolic TIA). As prompt initiation of therapy is essential in TIA to prevent subsequent strokes, determining their cause is important. In this study, we aim to determine the features of cardioembolic TIA and to compare them with those of noncardioembolic etiology.
Methods:
We retrospectively reviewed patients with a tissue-defined TIA who were admitted to our hospital from April 2007 to August 2013. The etiology was categorized according to Trial of Org 10172 in Acute Stroke Treatment, and TIA of cardioembolic origin and cervicocerebrovascular etiology (noncardioembolic TIA) were included in this study. Those with 2 or more possible causes or undetermined etiologies were excluded. Age, sex, comorbidities, ABCD2 score, and CHADS2 score were assessed and compared between the 2 groups.
Results:
There were no significant differences in the neurologic symptoms and their duration, morbidities of hypertension, diabetes, and dyslipidemia between the 2 groups. Coronary and peripheral artery diseases were more common in the cardioembolic TIA group (18.4% vs. 6.9%). Incidences of prior stroke and cerebral infarction determined by MRI were similar between the 2 groups. The ABCD2 score showed a similar distribution, but the CHADS2 score was significantly different; the cardioembolic TIA group showed a higher score (P = .005).
Conclusions:
Clinical features are similar in tissue-defined TIA of cardioembolic and noncardioembolic etiologies. The CHADS2 score can be useful in assessing the probability of cardioembolic TIA.
Related Concept Videos
Transient Ischemic Attack l: Introduction
Ischemic Stroke l: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome I: Introduction
Ischemic Stroke ll: Pathophysiology
Acute Coronary Syndrome III: Diagnostic Studies


